In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed the day trading at $7.3 up 1.39% from the previous closing price of $7.2. In other words, the price has increased by $1.39 from its previous closing price. On the day, 3.57 million shares were traded. XERS stock price reached its highest trading level at $7.47 during the session, while it also had its lowest trading level at $7.11.
Ratios:
For a better understanding of XERS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.95.
On November 11, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $3.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 12 ’25 when DAWN HALKUFF bought 42,500 shares for $7.28 per share.
McCulloch Kevin bought 25,000 shares of XERS for $109,475 on Jun 13 ’25. The insider now owns 1,708,585 shares after completing the transaction at $4.38 per share. On May 09 ’25, another insider, Fairley Ricki Louise, who serves as the Director of the company, bought 56,667 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1178803968 and an Enterprise Value of 1376744704. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.79. Its current Enterprise Value per Revenue stands at 5.596 whereas that against EBITDA is 164.27.
Stock Price History:
The Beta on a monthly basis for XERS is 0.40, which has changed by 1.862745 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $7.61, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 44.34%, while the 200-Day Moving Average is calculated to be 72.52%.
Shares Statistics:
Over the past 3-months, XERS traded about 2.40M shares per day on average, while over the past 10 days, XERS traded about 4688480 shares per day. A total of 161.22M shares are outstanding, with a floating share count of 148.84M. Insiders hold about 7.83% of the company’s shares, while institutions hold 55.98% stake in the company. Shares short for XERS as of 1753920000 were 18222832 with a Short Ratio of 7.58, compared to 1751241600 on 19965518. Therefore, it implies a Short% of Shares Outstanding of 18222832 and a Short% of Float of 11.74.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of Xeris Biopharma Holdings Inc (XERS).The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between -$0.01 and -$0.01 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.16, with 2.0 analysts recommending between $0.31 and $0.0.
Revenue Estimates
5 analysts predict $73.48M in revenue for the current quarter. It ranges from a high estimate of $74.8M to a low estimate of $71.4M. As of the current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $54.27MFor the next quarter, 5 analysts are estimating revenue of $78.98M. There is a high estimate of $83.1M for the next quarter, whereas the lowest estimate is $75.2M.
A total of 5 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $288.3M, while the lowest revenue estimate was $271.7M, resulting in an average revenue estimate of $282.8M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $341.03M in the next fiscal year. The high estimate is $367.7M and the low estimate is $314.8M.
